KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bausch Health Companies (BHC) Research & Development (2016 - 2026)

Bausch Health Companies' Research & Development history spans 18 years, with the latest figure at $163.0 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 13.99% to $163.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $564.0 million, a 7.24% decrease, with the full-year FY2025 number at $629.0 million, up 2.11% from a year prior.
  • Research & Development hit $163.0 million in Q1 2026 for Bausch Health Companies, up from $161.0 million in the prior quarter.
  • Over the last five years, Research & Development for BHC hit a ceiling of $163.0 million in Q4 2024 and a floor of $81.0 million in Q3 2025.
  • Historically, Research & Development has averaged $144.5 million across 5 years, with a median of $151.0 million in 2024.
  • Biggest five-year swings in Research & Development: increased 22.83% in 2023 and later plummeted 44.52% in 2025.
  • Tracing BHC's Research & Development over 5 years: stood at $142.0 million in 2022, then increased by 7.04% to $152.0 million in 2023, then grew by 7.24% to $163.0 million in 2024, then fell by 1.23% to $161.0 million in 2025, then grew by 1.24% to $163.0 million in 2026.
  • Business Quant data shows Research & Development for BHC at $163.0 million in Q1 2026, $161.0 million in Q4 2025, and $81.0 million in Q3 2025.